Provided by Tiger Fintech (Singapore) Pte. Ltd.

ATI Inc

89.55
+7.398.99%
Post-market: 88.20-1.3517-1.51%19:59 EDT
Volume:2.89M
Turnover:254.75M
Market Cap:12.34B
PE:30.94
High:89.75
Open:83.16
Low:83.15
Close:82.16
52wk High:96.20
52wk Low:39.23
Shares:137.83M
Float Shares:137.83M
Volume Ratio:2.37
T/O Rate:2.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.89
EPS(LYR):2.82
ROE:26.05%
ROA:7.61%
PB:7.08
PE(LYR):31.75

Loading ...

Director David J. Morehouse Reports Disposal of Common Shares of ATI Inc

Reuters
·
Aug 07

Robert S. Wetherbee, Executive Chairman, Reports Disposal of Common Shares of ATI Inc

Reuters
·
Aug 07

ATI Is Maintained at Overweight by Barclays

Dow Jones
·
Aug 04

ATI Is Maintained at Positive by Susquehanna

Dow Jones
·
Aug 01

ATI Inc : JP Morgan Raises Target Price to $92 From $75

THOMSON REUTERS
·
Aug 01

Stock Track | ATI Inc. Plummets 13.64% Pre-Market Despite Q2 Earnings Beat as Revenue Miss Overshadows Boeing Deal

Stock Track
·
Jul 31

Stock Track | ATI Inc. Plunges 6.62% Pre-Market Despite Q2 Earnings Beat as Revenue Falls Short

Stock Track
·
Jul 31

Stock Track | ATI Inc. Plunges 6.62% Pre-market on Q2 Revenue Miss Despite Earnings Beat and Boeing Deal

Stock Track
·
Jul 31

ATI Shares Down 6% Premarket After Q2 Revenue Miss

THOMSON REUTERS
·
Jul 31

ATI Inc. Expands Titanium Supply Agreement with Boeing for Aerospace Programs

Reuters
·
Jul 31

ATI Inc - Positioned to Serve Boeing's Third-Party Subsidiaries Under Terms of Agreement

THOMSON REUTERS
·
Jul 31

ATI Inc - to Supply High-Performance Titanium Materials to Boeing

THOMSON REUTERS
·
Jul 31

ATI and Boeing Extend and Expand Titanium Supply Long-Term Agreement

THOMSON REUTERS
·
Jul 31

ATI Q2 Adj. EPS $0.74 Beats $0.71 Estimate, Sales $1.140B Miss $1.149B Estimate

Benzinga
·
Jul 31

BRIEF-ATI Q2 Adjusted EPS USD 0.74 Vs. IBES Estimate USD 0.72

Reuters
·
Jul 31

ATI Inc: Outlook Q3 Adj EPS $0.69 - $0.75

THOMSON REUTERS
·
Jul 31

ATI Inc: Outlook FY Adj EPS $2.90 - $3.07

THOMSON REUTERS
·
Jul 31

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

GlobeNewswire
·
Jul 30

ATI Inc. Announces Upcoming Release of Second Quarter 2025 Financial Results

Reuters
·
Jul 02

ATI Inc. Secures Amended $800 Million Credit Agreement Extending Through 2030 with Major Financial Institutions

Reuters
·
Jun 21